KNIGHT CAPITOL CONSULTANTS for PHRMA
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Research and Development tax credit extension, and possible changes to pharmaceutical reimbursement provisions (H.R. 5297, small business lending; H.R.4213, tax extenders)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | previously listed |
Health Issues HCR
Health Care Reform - efforts to amend or implement pharmaceutical provisions of the Patient Protection and Affordable Health Care Act (PL 111-148) and the Health Care and Education Reconciliation Act of 2010 (PL 111-152), including comparative effectiveness, prescription drug importation, and reimbursement.Prescription Drug User Fee reauthorization* (*no legislation yet). Continuing resolution (P.L. 111-242).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | previously listed |
Copyright/Patent/Trademark CPT
Patent Reform -- issues of interest to the pharmaceutical industry (S. 515/H.R. 1260) Provisions in legislation affecting agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369/H.R. 3962/H.R. 3590/H.R. 4899)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA KNIGHT | Prof. Staff, House Appropr. Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.